In the convalescent cohort, SARS-CoV-2 infection had occurred a median time of 185 days prior to immune assessment (inclusion)
In the convalescent cohort, SARS-CoV-2 infection had occurred a median time of 185 days prior to immune assessment (inclusion). a significantly lower level than that observed even in unvaccinated SARS-CoV-2 convalescents (p<0.001). Furthermore, while the secondary memory B cell (MBC) populace consisted of 100%, 33%, and BI-D1870 76% IgG+, IgM+, and IgA+ expressing cells, respectively, in the unexposed group, the MBC response showed a significant decrease across all isotypes. Similarly, although secondary specific IgG+, IgM+, and IgA+-MBC isotypes were found in 100%, 39%, and 76% of the unexposed participants, respectively, the magnitude of the MBC levels was significantly lower for all the isotypes compared to convalescents. Interestingly, convalescents without an initial serological response experienced a lower MBC response, like what found in unexposed subjects. There was an inverse correlation between specific MBCs (r=-0.307; p=0.027), especially for isotype IgA+ (r=-0.279, p=0.045), and the time since the second vaccination dose. Furthermore, during a median follow-up of 434 days (IQR, 339-495), 49 out of 149 individuals (33%) became infected, 29 in na?ve and 20 in convalescent individuals, showing a significant correlation between spike-specific MBC magnitude after vaccination and the time for SARS-CoV-2 contamination, especially for IgA+/IgG+ MBC isotypes. Conclusions MBCs were primed by mRNA-based vaccination in most cases, but SARS-CoV-2 na?ve individuals had a blunted specific MBC response, and this was associated with a shorter time to breakthrough SARS-CoV-2 infection. Keywords: SARS-CoV-2, convalescents, COVID-19, longterm immunity, B cell response Introduction The introduction of vaccines has resulted in the prevention of SARS-CoV-2 contamination and the management of disease severity (1, 2). However, you will find conflicting results regarding the longevity of antibody response to SARS-CoV-2 (3), and, in addition, studies in Rabbit polyclonal to COT.This gene was identified by its oncogenic transforming activity in cells.The encoded protein is a member of the serine/threonine protein kinase family.This kinase can activate both the MAP kinase and JNK kinase pathways. vaccinated individuals have mainly focused on the serological response and neutralising antibodies (4). The immune response to contamination or vaccination results in the production of antibodies by antibody-secreting cells (ASC), which can provide quick serological immunity and the generation of long-lived MBC (5). MBC can persist for decades or potentially for life, in lymph nodes, spleen, bone marrow and lungs, or circulate in the blood (6). For example, after vaccination, COVID-19-recovered patients showed a striking growth of spike-specific MBCs (7), but less is known about the long-term dynamics of the MBC repertoire after vaccination in unexposed individuals despite repeated antigenic activation. Indeed, you will find data, suggesting that long-lived plasma cells may not have been efficiently generated following vaccination regimens (8). Here, we analyzed two longitudinal cohorts of na?ve individuals and recovered patients for up to 2 months after two doses of the mRNA-based BNT162b2 (Pfizer BioNTech) COVID-19 vaccine to understand how mRNA vaccination impacts the MBC pool shaped by previous exposure to SARS-CoV-2 and to decipher how MBCs from na?ve vaccinees differ and evolve compared to SARS-CoV-2 recovered patients. Methods This study included 149 healthcare workers, 64 COVID-19 convalescents, and 85 infection-na?ve individuals who were followed at the tertiary Ramon y Cajal University or college Hospital (Madrid, Spain) since March 2020. They were over 18 years of age, without immunodeficiency or immunosuppression, and without malignancy or immunosuppressive treatment. They had participated in an internal survey for the presence of antibodies against the SARS-CoV-2 N protein after the first wave of the disease (9), and after the inclusion in the study. They were then vaccinated with two doses of the mRNA-based BNT162b2 (Pfizer BioNTech) COVID-19 vaccine in January-February 2021. Among them, 38 na?ve, 8 convalescents without initial positive serology and 16 convalescents with initial positive serology, participated in the blood sampling and were analysed. Thus, three time-points were analyzed: an internal serological BI-D1870 survey (April 2020), inclusion into the study (October 2020), and 3-4 weeks after the second dose of mRNA vaccine (February 2021). This study design allowed us to investigate the kinetics of immune responses following contamination and after vaccination. Convalescent patients were BI-D1870 defined as those with suggestive.
